Search Results - "Mahoney, R M"

Fissure formation in coke. 2: Effect of heating rate, shrinkage and coke strength by Jenkins, D.R., Mahoney, M.R.

“…We investigate the effects of the heating rate, coke shrinkage and coke breakage strength upon the fissure pattern developed in a coke oven charge during…”
Get full text

Fissure formation in coke. 1: The mechanism of fissuring by Jenkins, D.R., Mahoney, M.R., Keating, J.C.

“…Pilot scale coke oven experiments, in which carbonisation has been arrested after 2 and 4 h, have been used to identify key aspects of the initial formation…”
Get full text

Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers by Halling, Kevin C., French, Amy J., McDonnell, Shannon K., Burgart, Lawrence J., Schaid, Daniel J., Peterson, Brett J., Moon-Tasson, Laurie, Mahoney, Michelle R., Sargent, Daniel J., O'Connell, Michael J., Witzig, Thomas E., Farr, Gist H., Goldberg, Richard M., Thibodeau, Stephen N.

“…BACKGROUND: Microsatellite instability (MSI) and allelic imbalance involving chromosome arms 5q, 8p, 17p, and 18q are genetic alterations commonly found in…”
Get full text

Fissure formation in coke. 3: Coke size distribution and statistical analysis by Jenkins, D.R., Shaw, D.E., Mahoney, M.R.

“…A model of coke stabilization, based on a fundamental model of fissuring during carbonisation is used to demonstrate the applicability of the fissuring model…”
Get full text

Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer by Sloan, J A, Loprinzi, C L, Kuross, S A, Miser, A W, O'Fallon, J R, Mahoney, M R, Heid, I M, Bretscher, M E, Vaught, N L

“…We report on a clinical trial developed to compare four different instruments that provide overall quality-of-life (QOL) scores, ranging from a simple,…”
Get more information

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma by Dickson, M.A., Mahoney, M.R., Tap, W.D., D'Angelo, S.P., Keohan, M.L., Van Tine, B.A., Agulnik, M., Horvath, L.E., Nair, J.S., Schwartz, G.K.

“…Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation…”
Get full text

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors : An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression by PERRY, A, JENKINS, R. B, LEVITT, R, KROOK, J, TSCHETTER, L. K, MORTON, R. F, BUCKNER, J. C, O'FALLON, J. R, SCHAEFER, P. L, KIMMEL, D. W, MAHONEY, M. R, SCHEITHAUER, B. W, SMITH, S. M, HILL, E. M, SEBO, T. J

“…The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression…”
Get full text

Assessing human-robotic performance for vocational placement by Schuyler, J.L., Mahoney, R.M.

“…Describes the results of an exploratory study of the use of standard occupational therapy assessment tests to measure the effective manipulation ability of…”
Get full text

A Phase II study of high‐dose paclitaxel in patients with advanced neuroendocrine tumors by Ansell, Stephen M., Pitot, Henry C., Burch, Patrick A., Kvols, Larry K., Mahoney, Michelle R., Rubin, Joseph

“…BACKGROUND New agents with antitumor activity in patients with neuroendocrine tumors are sorely needed. A Phase II study of high‐dose paclitaxel in patients…”
Get full text

Powered feeding devices: an evaluation of three models by Hermann, R P, Phalangas, A C, Mahoney, R M, Alexander, M A

“…To evaluate and compare three powered feeding devices (Beeson, Handy 1, Winsford) as perceived by disabled individuals who require assistance with eating…”
Get more information

CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon by Venook, A., Niedzwiecki, D., Lenz, H.J., Innocenti, F., Mahoney, M.R., O'Neil, B., Shaw, J., Polite, B., Hochster, H., Atkins, J., Goldberg, R., Mayer, R., Schilsky, R., Bertagnolli, M., Blanke, C.

Get full text

Associations of physical, chemical with thermal changes during coking as coal heats – Experiments on coal maceral concentrates by Xie, W., Stanger, R., Wall, T.F., Lucas, J.A., Mahoney, M.R.

“…•Physical, chemical and thermal events of heating coal macerals were synchronized.•Thermo-expansion of coal used up to 21% of the volatiles to drive bubble…”
Get full text

Rapid Reporting and Review of an Increased Incidence of a Known Adverse Event by Sargent, Daniel J., Goldberg, Richard M., Mahoney, Michelle R., Hillman, David W., McKeough, Timothy, Hamilton, Sonja F., Darcy, Jennifer M., Anderson, Victoria L., Krook, James E., O'Connell, Michael J.

“…The National Cancer Institute (NCI) sponsors cancer clinical trials throughout the United States. Many of these trials are conducted by one of the groups of…”
Get full text

Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 by Huang, J., Sargent, D. J., Mahoney, M. R., Thibodeau, S. N., Smyrk, T. C., Sinicrope, F., Nelson, G. D., Alberts, S. R.

“…Abstract only 363 Background: Irinotecan (CPT-11) has demonstrated antitumor activity against metastatic colorectal cancer used alone or with 5-fluorouracil…”
Get full text

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147 by Alberts, S. R., Thibodeau, S. N., Sargent, D. J., Mahoney, M. R., Sinicrope, F., Shields, A. F., Chan, E., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Quesenberry, J. T., Smyrk, T. C., Grothey, A., Nair, S. G.

“…Abstract only…”
Get full text

Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147 by Mahoney, M. R., Sloan, J. A., Hubbard, J. M., Liu, H., Shields, A. F., Chan, E., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Nair, S. G., Sargent, D. J., Alberts, S. R.

“…Abstract only…”
Get full text

Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745 by Hubbard, J. M., Alberts, S. R., Loui, W. S., Mahoney, M. R., Roberts, L. R., Smyrk, T. C., Gatalica, Z., Kumar, S., Dakhil, S. R., Flynn, P. J., Lafky, J. M., Bury, M. J.

“…Abstract only…”
Get full text

Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147 by Sloan, J. A., Mahoney, M. R., Sargent, D. J., Hubbard, J. M., Liu, H., Basch, E. M., Shields, A. F., Chan, E., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Alberts, S. R.

“…Abstract only…”
Get full text

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas by Attia, S., Mahoney, M. R., Okuno, S. H., Adkins, D., Ahuja, H. G., Ducker, T. P., Maples, W. J., Ochs, L., Wentworth-Hartung, N. L., Erlichman, C., Bailey, H. H.

“…Abstract only…”
Get full text

Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 by Huang, J., Sargent, D. J., Mahoney, M. R., Shields, A. F., Chan, E., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Quesenberry, J. T., Smyrk, T. C., Grothey, A., Sinicrope, F., Nair, S. G., Alberts, S. R.

“…Abstract only…”
Get full text